NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL
RESULTS USING DMSO-CONTAINING MEDIUM

J 2020

NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA et. al.

Basic information

Original name

NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM

Authors

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP and P. MERICKA

Edition

CryoLetters, LONDON, CRYO LETTERS, 2020, 0143-2044

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.066

UT WoS

000527407900009

Keywords in English

mesenchymal stem cells; advanced therapy medicinal product; dimethyl sulfoxide; cryopreservation

Abstract

V originále

BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.

Links

90128, large research infrastructures

Name: CZECRIN III

Citovat

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP and P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. CryoLetters. LONDON: CRYO LETTERS, 2020, vol. 41, No 1, p. 50-56. ISSN 0143-2044.

@article{1807986,
   author = {Jandova, M. and Sponer, P. and Vokurkova, D. and Bauer, P. O. and Filipova, A. and Filip, S. and Mericka, P.},
   article_location = {LONDON},
   article_number = {1},
   keywords = {mesenchymal stem cells; advanced therapy medicinal product; dimethyl sulfoxide; cryopreservation},
   language = {eng},
   issn = {0143-2044},
   journal = {CryoLetters},
   title = {NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM},
   url = {https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009},
   volume = {41},
   year = {2020}
}

TY  - JOUR
ID  - 1807986
AU  - Jandova, M. - Sponer, P. - Vokurkova, D. - Bauer, P. O. - Filipova, A. - Filip, S. - Mericka, P.
PY  - 2020
TI  - NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM
JF  - CryoLetters
VL  - 41
IS  - 1
SP  - 50-56
EP  - 50-56
PB  - CRYO LETTERS
SN  - 01432044
KW  - mesenchymal stem cells
KW  - advanced therapy medicinal product
KW  - dimethyl sulfoxide
KW  - cryopreservation
UR  - https://www.webofscience.com/wos/woscc/full-record/WOS:000527407900009
N2  - BACKGROUND: Human mesenchymal stem cells (hMSCs) have tremendous potential in regenerative medicine, making it desirable to cryopreserve and bank them to increase their access and availability. OBJECTIVE: This research is part of a clinical trial performed on six patients that aimed to use advanced therapy medicinal products (ATMPs) based on hMSCs in patients undergoing repeated total hip replacement. MATERIALS AND METHODS: To compare the characteristics of fresh and frozen hMSCs, we used the trypan blue exclusion test (cell viability), flow cytometry (cell viability and phenotyping), sterility determinations and the clonogenic assay of cell proliferation. RESULTS: Cryopreserved hMSCs showed good quality parameters after thawing in comparison with fresh hMSCs in suspension. When using a medium containing dimethyl sulfoxide (DMSO), the viability was higher than 90% in all cases. The cell purity determined by flow cytometry was also acceptable. CONCLUSION: These initial results show that the prepared cryopreserved ATMP exhibited good viability and phenotype characteristics.
ER  -

JANDOVA, M., P. SPONER, D. VOKURKOVA, P. O. BAUER, A. FILIPOVA, S. FILIP and P. MERICKA. NEW CRYOPRESERVATION TECHNOLOGY OF HMSCS: FIRST PRECLINICAL RESULTS USING DMSO-CONTAINING MEDIUM. \textit{CryoLetters}. LONDON: CRYO LETTERS, 2020, vol.~41, No~1, p.~50-56. ISSN~0143-2044.

Detailed Information on Publication Record